

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.



"The British population is facing a health crisis – it is getting older, more overweight and a growing culture of ‘presenteeism’ is resulting in many employees placing additional stress and strain on their bodies when rest and recuperation is what’s needed."
- Hera Crossan, Research Analyst

This report looks at the following areas:

- **People won't slow down to get well**
- **NHS 'crisis' provides an opportunity for OTC brands and pharmacies**
- **Own-label continues to undermine value growth**

The OTC (over-the-counter) analgesics and cold and flu remedies market contracted slightly in 2017 (-0.5% to £1.25 billion), as consumers continued to make the switch to own-label versions. However, buoyed by challenges to NHS services, the market is projected to return to growth in 2018 (+0.5% to £1.26 billion).

**BUY THIS
REPORT NOW**

VISIT:
store.mintel.com

CALL:
EMEA
+44 (0) 20 7606 4533

Brazil
0800 095 9094

Americas
+1 (312) 943 5250

China
+86 (21) 6032 7300

APAC
+61 (0) 2 8284 8100

EMAIL:
reports@mintel.com

DID YOU KNOW?

This report is part of a series of reports, produced to provide you with a more holistic view of this market

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Table of Contents

Overview

- What you need to know
- Products covered in this Report

Executive Summary

The market

Own-label continues to challenge market growth

Figure 1: Best- and worst-case forecast of UK value sales of OTC analgesics and cold and flu remedies, 2013-23

Changes to NHS England prescription services are a potential positive

Companies and brands

Nurofen leads the way in analgesics

Figure 2: Retail value sales of all OTC analgesics, % share by brand, year ending May 2018

Lemsip solidifies leadership in cold and flu remedies

Figure 3: Retail value sales of cold and flu remedies, % share by brand, year ending May 2018

Benylin stretches lead in cough liquids

Figure 4: Retail value sales of cough liquids, % share by brand, year ending May 2018

Strepsils grows market share in medicated confectionery

Figure 5: Retail value sales of medicated confectionery, % share by brand, year ending May 2018

Topical analgesics drive NPD

Figure 6: New product launches in the OTC analgesics market, by launch type, January 2015-April 2018

Increased NPD focus on non-ingested cold and flu remedies returns

Figure 7: New product development in the cough, cold and flu remedies market, by launch type, January 2015-April 2018

The consumer

Headache most commonly experienced

Figure 8: Types of pain suffered in the last 12 months, April 2018

Oral remedies still most sought

Figure 9: Treatments sought for types of pain, April 2018

Paracetamol the leading oral analgesic

Figure 10: OTC oral remedy formats used, April 2018

Wraps enjoy a younger age profile

Figure 11: OTC topical remedy formats used, April 2018

31% prepared for pain

Figure 12: Behaviours around experiencing pain, April 2018

Women drive experience of colds

Figure 13: Types of cold/flu and cough/sore throat (not as symptoms of cold/flu) suffered in the last 12 months, April 2018

Women suffer more symptoms

Figure 14: Cold and flu symptoms experienced in the last 12 months, by gender, April 2018

Oral remedies most chosen

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Figure 15: Treatments sought for cold/flu and cough/sore throat (not as symptoms of cold/flu), April 2018

Too busy to take care

Figure 16: Behaviours around dealing with colds and flu, April 2018

Own-label products trusted

Figure 17: Attitudes towards OTC remedies for treating pains and ailments, April 2018

What we think

Issues and Insights

People won't slow down to get well

The facts

The implications

NHS 'crisis' provides an opportunity for OTC brands and pharmacies

The facts

The implications

Own-label continues to undermine value growth

The facts

The implications

The Market – What You Need to Know

Own-label continues to challenge market growth

Topical analgesics see 3% value growth

Sugar concerns could be driving down sales of cold and flu remedies

Chemists see sales fall...

...but changes to NHS England prescription services are a potential positive for the channel

Obesity levels remain high

Ageing population likely to increase need for OTC analgesics...

...but low birth rate is a challenge

Increase in 'presenteeism' increases demand for OTC remedies

Market Size and Forecast

Own-label continues to challenge market growth

Figure 18: UK retail value sales of OTC analgesics and cold and flu remedies, at current and constant prices, 2013-23

Market forecast to return to growth

Figure 19: Best- and worst-case forecast of UK value sales of OTC analgesics and cold and flu remedies, 2013-23

Forecast methodology

Market Segmentation

Topical analgesics see 3% value growth

Figure 20: UK retail value sales of OTC analgesics, by segment, 2016-18

Sugar concerns could be driving down sales of cold and flu remedies...

Figure 21: UK retail value sales of OTC cough, cold and flu remedies, by segment, 2016-18

...whilst maximum-strength products may also be impacting on the category

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Channels to Market

Chemists see sales fall

Figure 22: UK retail value sales of OTC analgesics, cough, cold and flu relief and medicated confectionery, by outlet type, 2016-18

Market Drivers

Obesity levels remain high

Figure 23: Trends in body mass index (BMI), England, 1995-2016

Sugar concerns rise

Figure 24: Sugar Awareness Week, 30 October-5 November 2017

Ageing population likely to increase need for OTC analgesics

Figure 25: Trends in the age structure of the UK population, 2012-22

Low birth rate challenges the category

Figure 26: Trends in number of live births (thousands), and mean age of mothers at the birth of their child, England and Wales, 2010-16

Flu vaccinations advance

Figure 27: Flu vaccination rate, by selected demographics, 2017 vs 2016

NHS under increased pressure

Cuts to NHS minor ailment scheme

Figure 28: List of conditions for which prescribing should be restricted (according to NHS England), April 2018

Increase in 'presenteeism' increases demand for OTC remedies

Figure 29: Employment trends (thousands), by gender, 2012-22

Companies and Brands – What You Need to Know

Nurofen leads in analgesics

Lemsip solidifies leadership in cold and flu remedies

Topical analgesics drive NPD

Increased NPD focus on non-ingested cold and flu remedies returns

DDD Group doubles recorded adspend on analgesics

Adspend levels for cough, cold and flu remedies drop below NPD

Anadin well known but uninspiring

Covonia most likely to be recommended

Market Share

Nurofen leads in analgesics

Figure 30: Retail value sales of OTC analgesics, by brand, years ending May 2017 and 2018

Lemsip solidifies leadership in cold and flu remedies

Figure 31: Retail value sales of cold and flu remedies, by brand, years ending May 2017 and 2018

Benylin stretches lead in cough liquids

Figure 32: Retail value sales of cough liquids, by brand, years ending May 2017 and 2018

Strepsils grows market share in medicated confectionery

Figure 33: Retail value sales of medicated confectionery, by brand, years ending May 2017 and 2018

Launch Activity and Innovation

BUY THIS
REPORT NOW

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Analgesics

NPD levels off

Figure 34: New product launches in the OTC analgesics market, by launch type, January 2015-April 2018

Topical analgesics drive NPD

Figure 35: New product launches in the OTC analgesics market, by format type, January 2015-April 2018

Figure 36: Examples of topical OTC analgesics launches, 2017

Own-label increases focus on topical analgesics

Figure 37: New product launches in the OTC analgesics market, own-label vs branded, January 2015-April 2018

Figure 38: Examples of non-ingested own-label launches in the UK OTC analgesics market, 2017

Topical manufacturers lead the way

Figure 39: New product launches in the OTC analgesics market, by top 10 ultimate companies and other, 2017

Convenience claims dominate

Figure 40: Top 10 claims in the OTC analgesics market, 2017

Cough, cold and flu remedies

Decongestants lead NPD

Figure 41: New product development in the cough, cold and flu remedies market, by sub-category, January 2015-April 2018

NPD continues its steady rise

Figure 42: New product development in the cough, cold and flu remedies market, by launch type, January 2015-April 2018

Figure 43: Examples of new packaging launches in the cough, cold and flu remedies market, 2017

Increased NPD focus on non-ingested cold and flu remedies returns

Figure 44: New product development in the cough, cold and flu remedies market*, by format, January 2015-April 2018

Figure 45: Examples of non-ingested cough, cold and flu remedy launches, 2017

Own-label NPD falls back

Figure 46: New product development in the cough, cold and flu remedies market, branded vs own-label, January 2015-April 2018

Market fragmented

Figure 47: New product development in the cough, cold and flu remedies market, by top ultimate companies and other, 2017

Botanical and herbal claims popular

Figure 48: Top 10 claims in the cough, cold and flu remedies market, 2017

Figure 49: Examples of cough, cold and flu remedy launches with botanical and herbal claims, 2017

Advertising and Marketing Activity

Analgesics

Adspend levels off

Figure 50: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, January 2015-April 2018

TV continues to dominate

Figure 51: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, by media type, January 2015-April 2018

Figure 52: A Combogestic Story by Thornton & Ross, May 2018

DDD Group shows growth

Figure 53: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, by top advertisers and other, January 2016-April 2018

Figure 54: Mentholatum's MindYourBack Campaign, October 2017

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Topical analgesics market growth drive Voltarol adspend

Figure 55: Total above-the-line, online display and direct mail advertising expenditure on OTC analgesics, by top brands and other, 2017

Cough, cold and flu remedies

Adspend levels drop below NPD

Figure 56: Recorded above-the-line, online display and direct mail advertising expenditure on cold/flu and cough remedies, January 2015-April 2018

TV leads the way

Figure 57: Total above-the-line, online display and direct mail advertising expenditure on cold/flu and cough remedies, by media type, January 2015-April 2018

Figure 58: GSK Day & Night Nurse ad pop-up, January 2018

Figure 59: Covonia's social media initiative #FeelThePower, 2018

Market leaders swap places in adspend

Figure 60: Total above-the-line, online display and direct mail advertising expenditure on cold/flu and cough remedies, by top advertisers and other, January 2016-April 2018

Lemsip the leader

Figure 61: Total above-the-line, online display and direct mail advertising expenditure on cold/flu and cough remedies, by top brands and other, 2017

Figure 62: Lemsip TV advert for Dry Cough & Sore Throat Oral Solution, 2017

Nielsen Ad Intel coverage

Brand Research

Brand map

Figure 63: Attitudes towards and usage of selected brands, April 2018

Key brand metrics

Figure 64: Key metrics for selected brands, April 2018

Brand attitudes: Covonia cares

Figure 65: Attitudes, by brand, April 2018

Brand personality: Sudafed accessible

Figure 66: Brand personality – Macro image, April 2018

4head youthful

Figure 67: Brand personality – Micro image, April 2018

Brand analysis

Covonia most likely to be recommended

Figure 68: User profile of Covonia, April 2018

4head seen as youthful

Figure 69: User profile of 4head, April 2018

Sudafed regarded as consistently high quality

Figure 70: User profile of Sudafed, April 2018

Anadin well known but uninspiring

Figure 71: User profile of Anadin, April 2018

The Consumer – What You Need to Know

Headaches the most commonly experienced pain

Women more likely to experience pain

Paracetamol the leading oral analgesic

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Wraps enjoy a younger age profile

31% prepared for pain

Women drive experience of colds...

...whilst flu experience is driven by young men

Oral cold and flu remedies most chosen

Too busy to take care

Own-label products trusted

Types of Pain Suffered and Treatments Sought

Headache most commonly experienced

Figure 72: Types of pain suffered in the last 12 months, April 2018

Menstrual pain dominates for women...

...increasing opportunities for topical analgesics

Musculoskeletal pain increases with age

Back pain an 'ageless' concern

Oral remedies still most sought

Figure 73: Treatments sought for types of pain, April 2018

Analgesic Formats

Paracetamol the leading oral analgesic

Figure 74: OTC oral remedy formats used, April 2018

Wraps enjoy a younger age profile

Figure 75: OTC topical remedy formats used, April 2018

Behaviours around Experiencing Pain

31% prepared for pain

Figure 76: Behaviours around experiencing pain, April 2018

Experience of Colds and Flu and Treatments Sought

Women drive experience of colds...

Figure 77: Types of cold/flu and cough/sore throat (not as symptoms of cold/flu) suffered in the last 12 months, April 2018

...while younger men drive flu experience

Non-cold/flu-related coughs and sore throats could still nudge sufferers towards cold remedies

Women suffer more symptoms

Figure 78: Cold and flu symptoms experienced in the last 12 months, by gender, April 2018

Oral remedies most chosen

Figure 79: Treatments sought for cold/flu and cough/sore throat (not as symptoms of cold/flu), April 2018

Behaviours around Dealing with Colds and Flu

Too busy to take care

Figure 80: Behaviours around dealing with colds and flu, April 2018

Prevention over cure important for 32%

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com

OTC Analgesics and Cold and Flu Remedies - UK - July 2018

Report Price: £1995.00 | \$2693.85 | €2245.17

The above prices are correct at the time of publication, but are subject to change due to currency fluctuations.

Attitudes towards OTC Analgesics and Cold and Flu Remedies

Own-label products trusted

Figure 81: Attitudes towards OTC remedies for treating pains and ailments, April 2018

39% have confidence in homemade remedies

Seniors think claims are unrealistic

Appendix – Data Sources, Abbreviations and Supporting Information

Abbreviations

Consumer research methodology

Forecast methodology

Appendix – Market Size and Forecast

Figure 82: Best- and worst-case forecast of UK value sales of OTC adult oral analgesics, 2013-23

Figure 83: Best- and worst-case forecast of UK value sales of OTC paediatric analgesics, 2013-23

Figure 84: Best- and worst-case forecast of UK value sales of OTC topical analgesics, 2013-23

Figure 85: Best- and worst-case forecast of UK value sales of OTC cold remedies, 2013-23

Figure 86: Best- and worst-case forecast of UK value sales of OTC cough liquids, 2013-23

Figure 87: Best- and worst-case forecast of UK value sales of medicated confectionery, 2013-23

**BUY THIS
REPORT NOW**

VISIT: store.mintel.com

CALL: EMEA +44 (0) 20 7606 4533 | Brazil 0800 095 9094

Americas +1 (312) 943 5250 | China +86 (21) 6032 7300

APAC +61 (0) 2 8284 8100 |

EMAIL: reports@mintel.com